| Literature DB >> 28250797 |
Kornelis S M van der Geest1, Qi Wang1, Thijs M H Eijsvogels2, Hans J P Koenen3, Irma Joosten3, Elisabeth Brouwer1, Maria T E Hopman2, Joannes F M Jacobs3, Annemieke M H Boots1.
Abstract
BACKGROUND: Age-related changes of the immune system, termed immunosenescence, may underlie the increased risk of infections and morbidity in the elderly. Little is known about the effects of acute exercise on peripheral immune parameters in octogenarians. Therefore, we investigated acute exercise-induced changes in phenotype and function of the immune system in octogenarians participating in the 2013 edition of the Nijmegen Four Days Marches. Blood sampling was performed at baseline and immediately after 4 days of the walking exercise (30 km/day). A comprehensive set of adaptive and innate immune traits were enumerated and analyzed by flow-cytometry. Peripheral blood mononuclear cells, isolated before and after walking were stimulated with LPS and supernatants were analysed for IL-1β, IL-6, IL-8 and TNF-α concentrations by ELISA. CMV serostatus was determined by ELISA.Entities:
Keywords: Ageing; Immune System; Monocytes; NK cells; Recent thymic emigrants; T cells
Year: 2017 PMID: 28250797 PMCID: PMC5322590 DOI: 10.1186/s12979-017-0087-2
Source DB: PubMed Journal: Immun Ageing ISSN: 1742-4933 Impact factor: 6.400
Demographics, health status and exercise characteristics of volunteers
| Men ( | Women ( | |
|---|---|---|
| Demographic characteristics | ||
| Age (yr) | 81.0 ± 1.2 | 81.6 ± 2.7 |
| Height (cm) | 174 ± 5.2 | 159 ± 6.7 |
| Weight (kg) | 75.8 ± 6.6 | 55.5 ± 6.6 |
| Body-mass index (kg/m2) | 25.0 ± 1.6 | 21.8 ± 1.9 |
| Lean body mass (kg) | 57.2 ± 4.7 | 37.8 ± 5.2 |
| Health status | ||
| Physical activity (hrs/week) | 8.5 ± 8.0 | 5.8 ± 5.9 |
| ≥ 5 times/week ≥30 min exercise (%) | 73 | 56 |
| Blood pressure | ||
| Systolic (mmHg) | 140 ± 18 | 146 ± 17 |
| Diastolic (mmHg) | 81 ± 11 | 82 ± 10 |
| Resting heart rate (bpm) | 64 ± 20 | 63 ± 14 |
| Gait speed (km/h) | 4.8 ± 0.7 | 4.5 ± 0.7 |
| Grip strength (kg) | 41 ± 8.0 | 25 ± 4.5 |
| CMV seropositive | 6 (55%) | 7 (78%) |
| Use of prescribed medicine | ||
| Anti-hypertensive drugs | 2 (18%) | 3 (33%) |
| Statins | 2 (18%) | 1 (11%) |
| Analgesics | 3 (27%) | 0 (0%) |
| Anti-diabetics | 0 (0%) | 0 (0%) |
| Othera | 2 (18%) | 1 (11%) |
| Pathology | ||
| Hypertension | 2 (18%) | 3 (33%) |
| Cardiovascular disease | 2 (18%) | 0 (0%) |
| Hypercholestorolemiab | 2 (18%) | 1 (11%) |
| Diabetes | 0 (0%) | 0 (0%) |
| Cancer (not further differentiated) | 2 (18%) | 1 (11%) |
| Othera | 1 (9%) | 2 (22%) |
| Exercise characteristics | ||
| Exercise duration per day (hh:mm) | 7:28 ± 1:10 | 8:07 ± 0:52 |
| Speed (km/h) | 4.2 ± 0.1 | 3.7 ± 0.1 |
| Average heart rate day 1 (bpm) | 99.5 ± 11.9 | 113.6 ± 14.3 |
| Peak heart rate day 1 (bpm) | 112.5 ± 13.1 | 125.0 ± 14.1 |
| Exercise intensity day 1 (% of age-adjusted max. heart rate) | 65.7 ± 7.7 | 75.4 ± 9.6 |
| Fluid balance | ||
| Fluid intake (L)c | 1.88 ± 0.8 | 1.98 ± 0.8 |
| Change in body mass (absolute kg)c | -0.80 ± 0.9 | -0.19 ± 0.6 |
| Change in body mass (relative %)c | -1.04 ± 1.1 | -0.38 ± 1.0 |
| Change in plasma volume (relative %)d | +3.1 ± 3.2 | +4.5 ± 3.5 |
aVolunteers who were diagnosed and treated for cancer, rheumatoid arthritis, allergy and glaucoma. bHypercholesterolemia is defined as total cholesterol levels of >6.5 mmol, as previously diagnosed by a physician. cDaily fluid intake and changes in body mass during walking. dChanges in plasma volume during walking estimated according to Dill and Costill [27]. Data are presented as mean ± standard deviation
Overview of staining panels and reagents for flowcytometry
| Panel | Mab reagent | Clone | Provider |
|---|---|---|---|
| T cell differentiation | CD3-Efluor 605 | okt-03 | Ebioscience, San Diego, CA, USA |
| CD8-APC-H7 | RPA-T8 | Ebioscience, San Diego, CA, USA | |
| CD45RO-FITC | UCHL-1 | BD bioscience, San Jose, CA, USA | |
| CCR7-PE-Cy7 | 3D12 | BD bioscience, San Jose, CA, USA | |
| CD31-AF647 | WM-59 | BD bioscience, San Jose, CA, USA | |
| CD28-AF700 | 28.2 | Biolegend, San Diego, CA, USA | |
| PD1-PE | EH12.2H7 | Biolegend, San Diego, CA, USA | |
| CD4-PcP | SK3 | BD bioscience, San Jose, CA, USA | |
| CTLA-4-BV421 | BNI3 | BD bioscience, San Jose, CA, USA | |
| Treg/Proliferation | CD8-PE-Cy7 | RPA-T8 | BD bioscience, San Jose, CA, USA |
| CD25-APC | BC96 | Ebioscience, San Diego, CA, USA | |
| CD45RA-Efluor605 | HI100 | Ebioscience, San Diego, CA, USA | |
| CD19-FITC | HD37 | Dako, Santa Clara, CA, USA | |
| CD4-APC-H7 | RPA-T4 | BD bioscience, San Jose, CA, USA | |
| FOXP3-PE | PCH101 | BD bioscience, San Jose, CA, USA | |
| Ki-67-PcP-Cy5.5 | B56 | BD bioscience, San Jose, CA, USA | |
| NK cell | CD16-FITC | 3G8 | Beckman Coulter, Brea, CA, USA |
| Inhibitory receptors | CD56-ECD | N901 | Beckman Coulter, Brea, CA, USA |
| CD3-APC-AF750 | UCHT1 | Beckman Coulter, Brea, CA, USA | |
| CD45-KO | J.33 | Beckman Coulter, Brea, CA, USA | |
| CD159c (NKG2C)-PE | 134591 | R&D Systems, Minneapolis, MN, USA | |
| CD158b (KIR2DL2/3)-PE-Cy7 | GL183 | Beckman Coulter, Brea, CA, USA | |
| CD158e1 (KIR3DL1)-APC | Z27.3.7 | Beckman Coulter, Brea, CA, USA | |
| CD158a (KIR2DL1)-APC-AF700 | EB6B | Beckman Coulter, Brea, CA, USA | |
| CD159a (NKG2A)-PB | Z199 | Beckman Coulter, Brea, CA, USA | |
| NK cell | CD16-FITC | 3G8 | Beckman Coulter, Brea, CA, USA |
| Activating receptors | CD56-ECD | N901 | Beckman Coulter, Brea, CA, USA |
| CD3-APC-AF750 | UCHT1 | Beckman Coulter, Brea, CA, USA | |
| CD45-KO | J.33 | Beckman Coulter, Brea, CA, USA | |
| CD336 (NKp44)-PE | Z231 | Beckman Coulter, Brea, CA, USA | |
| CD337 (NKp30)-PE-Cy5.5 | Z25 | Beckman Coulter, Brea, CA, USA | |
| CD335 (NKp46)-PE-Cy7 | BAB281 | Beckman Coulter, Brea, CA, USA | |
| CD314 (NKG2D)-APC | ON72 | Beckman Coulter, Brea, CA, USA | |
| CD244 (2B4) -APC-AF700 | C1.7.1 | Beckman Coulter, Brea, CA, USA | |
| CD161-PB | 191B8 | Beckman Coulter, Brea, CA, USA |
General and Immune parameters before and after walking
| Pre-Walking | Post-Walking |
| |
|---|---|---|---|
| Hemoglobin (mmol/L) | 8.7 (7.7–9.4) | 8.2 (7.3–9.1) | 0.0009 |
| Thrombocytes (109/L) | 233 (157–318) | 234 (160–349) | ns |
| CRP (mg/L) | 1 (1–9) | 1 (1–47) | 0.0078 |
| Creatinin (μmol/L) | 86 (47–147) | 100 (54–207) | 0.0008 |
| ASAT (U/L) | 28 (14–39) | (-) | (-) |
| ALAT (U/L) | 28 (21–46) | (-) | (-) |
| Leukocytes (109/L) | 6.6 (4.6–11.0) | 7.7 (5.7–14.3) | 0.0002 |
| Neutrophils (109/L) | 4.1 (2.4–8.3) | 5.1 (2.9–10.4) | 0.0008 |
| Eosinophils (109/L) | 0.15 (0.03–0.68) | 0.18 (0.06–0.78) | 0.0166 |
| Basophils (109/L) | 0.04 (0.01–0.07) | 0.03 (0.02–0.05) | ns |
| Monocytes (109/L) | 0.49 (0.29–0.90) | 0.67 (0.40–1.21) | 0.0005 |
| Lymphocytes (109/L) | 1.57 (1.00–2.21) | 1.82 (1.07–2.97) | 0.0045 |
| CD3+ T cells (109/L) | 0.75 (0.20–1.36) | 1.11 (0.48–1.98) | 0.0005 |
| CD4+ T cells (109/L) | 0.46 (0.06–0.99) | 0.59 (0.37–1.62) | 0.0007 |
| CD8+ T cells (109/L) | 0.15 (0.03–0.45) | 0.15 (0.05–0.71) | 0.0061 |
| CD19+ B cells (109/L) | 0.23 (0.05–0.40) | 0.30 (0.09–0.51) | 0.0023 |
| CD16 + CD56+ NK cells (109/L) | 0.40 (0.21–0.87) | 0.31 (0.13–0.70) | 0.0178 |
Medians + range are indicated (n = 20). The minimal increase in exercise-induced plasma volume (3.7%) did not influence any of the significant differences found
Immune parameters before and after walking in CMV seropositive and seronegative participants
| CMV+ | CMV- | |||
|---|---|---|---|---|
| Before | After | Before | After | |
| Hemoglobina (mmol/L) | 8.4 (7.7–9.4) | 7.9 (7.3–8.7)** | 8.9 (7.9–9.0) | 8.7 (7.5–9.1) |
| CRP (mg/L) | 1 (1–9) | 1 (1–10) | 1 (1–6) | 9 (1–47) |
| Leukocytes (109/L) | 6.6 (4.6–11.0) | 7.9 (5.7–14.3)** | 6.6 (4.8–9.1) | 7.2 (6.3–12.3)* |
| Neutrophils (109/L) | 3.8 (2.4–8.3) | 5.0 (2.9–10.4)* | 4.2 (3.2–6.6) | 5.1 (4.2–9.2)* |
| Eosinophils (109/L) | 0.12 (0.03–0.68) | 0.19 (0.06–0.78)** | 0.17 (0.08–0.28) | 0.15 (0.08–0.33) |
| Basophils (109/L) | 0.03 (0.01–0.06) | 0.03 (0.02–0.05) | 0.05 (0.02–0.07) | 0.04 (0.03–0.05) |
| Monocytes (109/L) | 0.48 (0.29–0.69) | 0.68 (0.40–1.05)** | 0.57 (0.32–0.90) | 0.66 (0.42–1.21) |
| Lymphocytes (109/L) | 1.65 (1.45–2.21) | 2.19 (1.33–2.97)** | 1.37 (1.00–1.92) | 1.40 (1.07–2.08) |
| CD3+ T cells (109/L) | 0.77 (0.49–1.36) | 1.19 (0.73–1.98)** | 0.63 (0.20–1.00) | 0.76 (0.48–1.45) |
| CD4+ T cells (109/L) | 0.52 (0.17–0.99) | 0.73 (0.40–1.62)** | 0.40 (–0.06–0.69) | 0.57 (0.37–0.87) |
| CD8+ T cells (109/L) | 0.21 (0.04–0.45) | 0.21 (0.06–0.72)* | 0.08 (0.04–0.17) | 0.10 (0.05–0.19) |
| CD19+ B cells (109/L) | 0.26 (0.09–0.40) | 0.35 (0.11–0.51)* | 0.10 (0.05–0.40) | 0.16 (0.09–0.45)* |
| CD16 + CD56+ NK cells (109/L) | 0.32 (0.21–0.87) | 0.31 (0.13–0.70) | 0.43 (0.38–0.52) | 0.29 (0.22–0.43)* |
CMV+ subjects (n = 13) and CMV- subjects (n = 7). Medians and range are shown. Paired analysis was peformed separately for CMV+ and CMV- subjects before and after excersise. Statistical significance by Wilcoxon signed rank test is indicated as *p < 0.05 or **p < 0.01
aChanges in plasma volumes estimated according to Dill and Costill were not significantly different between CMV+ and CMV- subjects
Fig. 1Exercise reduces rates of T cell proliferation and leads to redistribution of T cell subsets. a Rates of CD4 (left panel) and CD8 (right panel) proliferation before (Pre-Walking) and after exercise (Post-Walking) assessed by Ki-67 expression using flow-cytometry. Percentages of Ki-67 expressing cells within the CD4 and CD8 populations are shown. b Enumeration of CD4 (upper panel) and CD8 (lower panel) T cell differentiation subsets based on CD45RO and CCR7 expression Pre- and Post-Walking. Mean (+/- SEM) numbers (109 cells/L) of naïve T cells (TNaïve), central memory T cells (TCM), effector memory T cells (TEM) and terminally differentiated T cells (TTD) are shown. c Mean (+/- SEM) numbers (109 cells/L) of recent thymic emigrants defined as CD31 + CD4 + TNaïve and the central naïve CD31-CD4+ TNaïve subsets. Statistical significance by Wilcoxon signed rank test is indicated as *p < 0.05, **p < 0.01, ***p < 0.001
Fig. 2Exercise-induced changes of naïve Treg, but not memory Treg. a Representative CD45RA and FoxP3 staining in CD4 T cells before and after exercise (Pre-walking and Post-walking). Naïve Treg cells are identified by CD45RA + Foxp3dim and memory Treg cells by CD45RA-FoxP3high [31]. b Mean (+/- SEM) numbers (109 cells/L) of Naïve Treg and Memory Treg Pre-walking and Post-walking. Statistical significance by Wilcoxon signed rank test is indicated as ***p < 0.001
Fig. 3Exercise-induced changes in NK cells. a Mean (+/- SEM) numbers (109 cells/L) of CD56dim and CD56bright NK subsets Pre-walking and Post-walking in the study population (n = 20, left panels) and when stratified for CMV serostatus (CMV+; n = 13, CMV-; n = 7, right panels). b Percentages of KIR2DL1+, KIR2DL2/3+, KIR3DL1+, NKG2A+ and NKG2C+ NK cells within CD56dim NK cells Pre-walking and Post-walking in CMV+ and CMV- subjects. c Percentages of NKp30+, NKp44, NKp46+,2B4+, NKG2D+ within CD56dim NK cells Pre-walking and Post-walking in CMV+ and CMV- subjects. Statistical significance by Wilcoxon signed rank test is indicated as *p < 0.05, **p < 0.01
Fig. 4LPS-stimulated PBMC cytokine production before and after walking. Cytokines (a) IL-6, (b) IL-8, (c) IL-1β and (d) TNFα in the 24 h supernatant of LPS-stimulated PBMC isolated pre and post walking. Individual pre- and post- samples are connected by lines. Cytokines in supernatants were assessed with ELISA and expressed as ng/mL. The assay sensitivity was 8 pg/mL for IL-1β, 31 pg/mL for IL-6 and TNF-α, and 312 pg/mL for IL-8. The net cytokine production was calculated as cytokine production of the stimulated sample minus the cytokine production of the non-stimulated sample. IL-6 and IL-8 were assessed in 12 walkers (8 males and 4 females). IL-1β and TNF-α were assessed in 6 walkers (4 males and 2 females). Statistical significance by Wilcoxon signed rank test is indicated as *p < 0.05